Hong Kong Stock Movement: AB&B BIO-TECH-B fell 14.09%, overseas vaccine agreements raised profit concerns, market sentiment changed abruptly

Hong Kong Stock Movement AB&B BIO-TECH-B fell 14.09%. Based on recent key news: On March 16, AB&B BIO-TECH-B reached an overseas vaccine agreement with Watson Hong Kong, causing the stock price to drop by 13%. This agreement raised market concerns about the company's future profitability, leading to a significant decline in stock price. The vaccine industry is highly competitive, and market volatility has intensified. Stocks with High Trading Volume in the Industry Kangfang Biotech rose 1.97%. Based on recent key news: On March 16, Kangfang Biotech announced that its trispecific antibody AK150 received clinical trial approval from the National Medical Products Administration. This news boosted the stock price as the market holds an optimistic view on the potential of its innovative drugs. On March 16, the Hong Kong stock market was supported by a significant net inflow of southbound funds, with inflows exceeding RMB 180 billion, enhancing market confidence and driving up stocks like Kangfang Biotech. On March 16, the overall valuation repair trend in the Hong Kong stock market continued, despite short-term fluctuations caused by geopolitical factors, the sustained inflow of southbound funds provided stable support for the market. The Hong Kong stock market, supported by southbound funds, experienced increased volatility. Innovent Biologics rose 1.25%. Based on recent key news: On March 16, the Hong Kong stock market experienced overall fluctuations due to geopolitical conflicts, but the sustained net inflow of southbound funds supported the liquidity of the Hong Kong stock market. Innovent Biologics benefited from the inflow of funds, leading to a rise in stock price. Source: First Financial. On March 17, the government work report listed biomedicine as an emerging pillar industry, and the policy catalyzed a recovery in sector risk appetite. Innovent Biologics was recommended as a buy target, and the stock price rose due to favorable policies. Source: CMB International. On March 17, the MSCI China Healthcare Index outperformed the market, and after a correction in the innovative drug sector, the release of policy dividends led to a rise in Innovent Biologics' stock price. Source: CMB International. Significant inflow of funds into the Hong Kong stock market, increased volatility. 3SBio rose 4.92%. Based on recent news: On March 16, 3SBio deepened cooperation with BWH and Dr. Peter Sage, targeting the field of autoimmune diseases, planning to advance gene-modified Treg cell therapy phase I clinical trials by 2027. This news boosted market confidence in the company's future development, driving up the stock price. On March 16, southbound funds continued to flow into the Hong Kong stock market, with a cumulative net inflow exceeding RMB 180 billion this year, becoming an important support for the liquidity of the Hong Kong stock market. The increase in fund inflows provided strong financial support for Hong Kong companies like 3SBio, further driving up stock prices. On March 17, CMB International released a research report indicating that the government work report listed biomedicine as an emerging pillar industry, with policy dividends continuing to be released. The firm recommended buying 3SBio, with a target price of RMB 37.43. The positive ratings from analysts enhanced market expectations for 3SBio, driving up the stock price. Continuous net inflow of southbound funds and the release of policy dividends Stocks Ranked Among the Top by Market Capitalization in the Industry BeiGene rose by 0.17%. Based on recent news, On March 17, the power equipment industry is ushering in development opportunities against the backdrop of global grid upgrades and increasing demand for AI computing power, with related companies' capital expenditures expected to rise, driving up related sectors. Global Times On March 16, southbound funds continued to see a net inflow into Hong Kong stocks, with a cumulative net inflow exceeding 180 billion yuan this year, becoming an important support for the funding of Hong Kong stocks. Yicai On March 15, companies on the STAR Market showed an overall trend of increasing revenue and reducing losses, supporting the refinancing needs of technology innovation enterprises and boosting market confidence. The funding support for Hong Kong stocks from the Shanghai Stock Exchange is strong, and industry rotation is accelerating